The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|23|42|4718-4734

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.23, Iss.42, 2016-12, pp. : 4718-4734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

By Tandon Manish   Vemula Sai Vikram   Mittal Suresh K  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 31-51

Informa Healthcare

Access to resources Recommend Favorite

EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics

By  

Current Cancer Drug Targets, Vol. 5, Iss. 3, 2005-05 ,pp. : 149-157

Bentham Science Publishers

Access to resources Recommend Favorite

EphA2 as a target for ovarian cancer therapy

By Landen Charles N   Kinch Michael S   Sood Anil K  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1179-1187

Informa Healthcare

Access to resources Recommend Favorite

Editorial; Impact of Drug Metabolism and its Relevance upon Drug Discovery

By  

Current Drug Metabolism, Vol. 18, Iss. 12, 2018-02 ,pp. : 1070-1070

Bentham Science Publishers

Access to resources Recommend Favorite

STAT proteins as novel targets for cancer drug discovery

By Turkson James  

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 5, 2004-10 ,pp. : 409-422

Informa Healthcare

Access to resources Recommend Favorite